Isomorphic Labs Raises $2.1B Series B

Isomorphic Labs, a London-based AI-first drug design and development company, has raised $2.1 billion in Series B funding. The company, which focuses on reimagining drug discovery through proprietary AI models, plans to use the capital to scale its operations and advance its pipeline of therapeutic programs.

Investors

The funding round was led by Thrive Capital. Participating investors include existing backers Alphabet and GV, as well as new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

Isomorphic Labs Use of Funds

The new capital will be used to further develop and deploy the IsoDDE AI drug design engine. The company also intends to scale its business globally, expand its drug candidate pipeline, and integrate additional AI, engineering, and clinical talent across its international office locations.

About Isomorphic Labs

Founded in 2021 by CEO Sir Demis Hassabis, Isomorphic Labs aims to transform the drug discovery process by applying first-principles AI to complex biological and medical challenges. The company has developed a unified AI drug design engine capable of predictive modeling across multiple therapeutic areas.

Funding Details

Company Website: https://isomorphiclabs.com

Company: Isomorphic Labs
Raised: $2.1B
Round: Series B
Funding Date: May 12, 2026
Lead Investor: Thrive Capital
Additional Investors: Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund
Company Website: www.isomorphiclabs.com
Software Category: AI Drug Discovery
Source: https://www.prnewswire.com/in/news-releases/isomorphic-labs-secures-2-1-billion-funding-to-scale-its-ai-drug-design-engine-302769702.html